Swiss drug maker Novartis AG Thursday reported a sharp decline in the first-quarter net profit, that reflected the absence of prior year’s hefty asset disposal gain. Drop in net sales also hurt profit mainly due to loss of exclusivity for its cancer drug Gleevec/Glivec in the US. Looking forward, the company still expects flat net sales and core operating income for fiscal 2016.